ArticleOncoimmunology
Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Immune gene expression and response to chemotherapy in advanced breast cancer.British journal of cancer · 2018Trial
- Association between transcriptomic metrics of exogenous antigen presentation and adaptive immunity with locoregional recurrence in localized estrogen receptor negative breast cancer: retrospective review of multi-institutional datasets.Breast cancer research : BCR · 2025Article
- Classification of triple-negative breast cancer based on pathway enrichment levels.Medical oncology (Northwood, London, England) · 2023Article
- Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer.Frontiers in artificial intelligence · 2023Article
- PD-L1 Gene Polymorphisms rs822336 G>C and rs822337 T>A: Promising Prognostic Markers in Triple Negative Breast Cancer PatientsMedicina (Kaunas, Lithuania) · 2022Article
- Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.Frontiers in public health · 2022Article
- Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy.Frontiers in genetics · 2022Review
- Article
- Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers.Frontiers in genetics · 2021Article
- Identification of a prognosis‑associated signature associated with energy metabolism in triple‑negative breast cancer.Oncology reports · 2020Article
- Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.Theranostics · 2020Article
- Recent advances in nanotheranostics for triple negative breast cancer treatment.Journal of experimental & clinical cancer research : CR · 2019Review
- Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation.Cancers · 2019Article
- Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.Breast cancer research : BCR · 2019Article
- Classification of triple-negative breast cancers based on Immunogenomic profiling.Journal of experimental & clinical cancer research : CR · 2018Article
- A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer.Translational oncology · 2018Article
- The Hierarchical Modular Structure of HER2+ Breast Cancer Network.Frontiers in physiology · 2018Article
- The immune contexture in cancer prognosis and treatment.Nature reviews. Clinical oncology · 2017Review
- New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels.Scientific reports · 2017Article
- PD-L1 and intratumoral immune response in breast cancer.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous group of aggressive breast cancers for which no targeted treatment is available. Robust tools for TNBC classification are required, to improve the prediction of prognosis and to develop novel therapeutic interventions. We analyzed 3,247 primary human breast cancer samples from 21 publicly available datasets, using a five-step method: (1) selection of TNBC samples by bimodal filtering on ER-HER2 and PR, (2) normalization of the selected TNBC samples, (3) selection of the most variant genes, (4) identification of gene clusters and biological gene selection within gene clusters on the basis of String© database connections and gene-expression correlations, (5) summarization of each gene cluster in a metagene. We then assessed the ability of these metagenes to predict prognosis, on an external public dataset (METABRIC). Our analysis of gene expression (GE) in 557 TNBCs from 21 public datasets identified a six-metagene signature (167 genes) in which the metagenes were enriched in different gene ontologies. The gene clusters were named as follows: Immunity1, Immunity2, Proliferation/DNA damage, AR-like, Matrix/Invasion1 and Matrix2 clusters respectively. This signature was particularly robust for the identification of TNBC subtypes across many datasets (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.